Profile: Clearside Biomedical Inc (CLSD.A)
17 Jun 2019
Clearside Biomedical, Inc., incorporated on May 26, 2011, is a clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye. The Company's product candidates focus on diseases affecting the retina, which is the tissue that lines the inside of the eye and is primarily responsible for vision, and the choroid, which is the layer adjacent to the retina that supplies the retina with blood, oxygen and nourishment. With its microinjector, drugs are injected into and spread within and through the suprachoroidal space, (SCS), which is the space located between the choroid and the outer protective layer of the eye known as the sclera. With the suprachoroidal injection, its product candidates are more directly administered to the retina and choroid as compared to other ocular drug administration techniques, such as injections of drug into the vitreous, a jelly-like substance that occupies the central portion of the eye. It holds the rights to develop and commercialize drugs for treatment via injection into the SCS. The Company's product candidates are based on commonly used ophthalmic drugs. Its development programs aim to restore or improve visual function primarily by reducing the macular edema associated with a number of diseases affecting the retina and choroid.
The Company is developing Zuprata, a preservative-free formulation of the corticosteroid triamcinolone acetonide (TA) for the treatment of macular edema associated with non-infectious uveitis. It has specifically designed Zuprata to be administered using its SCS Microinjector. It is enrolling patients with macular edema associated with non-infectious uveitis in a pivotal Phase III clinical trial. It is also developing Zuprata for the treatment of macular edema associated with retinal vein occlusion (RVO), a sight-threatening disorder resulting from the blockage of a retinal vein. It is engaged in exploring whether a suprachoroidal injection of Zuprata and a concomitant intravitreal injection of Eylea (aflibercept), an inhibitor of vascular endothelial growth factor (VEGF), can provide improved visual acuity, reduced macular edema and reduced injection frequency as compared to administration of intravitreal Eylea alone. Its Zuprata development program also includes another retinal vascular condition known as diabetic macular edema (DME). DME is a common ocular complication of diabetes that results in swelling in the macula and is the primary cause of vision loss associated with diabetes.
The Company is also developing another product candidate, an injectable suspension formulation of the compound axitinib, to be administered suprachoroidally for the treatment of neovascular age-related macular degeneration, or wet AMD. Axitinib has activities against both VEGF receptors and receptors of platelet derived growth factor, or PDGF. It is also working with third parties through collaborations and licenses to develop eye disease treatments using its SCS Microinjector and method of drug administration to the choroid and retina through the SCS. It has completed a Phase II clinical trial in patients with macular edema associated with non-infectious uveitis to evaluate the safety and efficacy of Zuprata injected into the SCS with its SCS Microinjector. It has completed a Phase II clinical trial for the treatment of macular edema associated with RVO, a sight-threatening disorder resulting from the blockage of a retinal vein.
Clearside Biomedical Inc
900 N Point Pkwy Ste 200
ALPHARETTA GA 30005-8995